Comparison Influence to Prognosis of CTP and MRP in AIS Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

1000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2009-06-30

Study Completion Date

2026-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Acute ischemia stroke (AIS) is the leading cause of death in China. Thrombolytic therapy with recombinant tissue plasminogen activator (rt-PA) has been proven to reduce disability in AIS patients within 4.5 hours after symptom onset. However, only 2% of AIS patients received thrombolytic therapy in China.

Perfusion imaging is demonstrated to increase the rate of thrombolytic therapy by identifying the ischemic infarct core (the brain tissue that is irreversibly injured) and the ischemia penumbra (the brain tissue surrounding the ischemia infarct core that is hypoperfused but still viable) for those patients with extending therapeutic window (beyond the current 4.5 hours after symptom onset), as well as minor stroke or those with atypical symptoms.

Three prospective clinical trials, DEFUSE, DEFUSE-2 and EPITHET, has confirmed that mismatch between perfusion weighted-imaging (PWI) and diffusion weighted-imaging (DWI) correspond to the ischemic penumbra whereas DWI provides information of the ischemia infarct core and major reperfusion relate to good clinical outcome in extending therapeutic window AIS patients with DWI-PWI mismatch.

Computed tomography perfusion (CTP) may be a potential alternative technology for recognition of reversibly damaged brain tissue in AIS patients, with the prominent advantage of fast scan. Recent studies also demonstrated that CTP could select eligible candidates for reperfusion therapy. More recently, with data of EXTEND-IA, reperfusion therapy in AIS patients with CTP mismatch (using a CT time to maximum \>6 s as ischemic hypoperfusion volume and a CT relative cerebral blood flow \<30% of that in normal tissue as ischemic core volume) were related to good clinical outcome.

However, plenty of studies demonstrated CT cerebral blood volume did not always predict ischemic infarct core in AIS patients. A recent study also confirmed the poor contrast: noise ratios of CT cerebral blood volume and CT cerebral blood flow result in large measurement error, compared with those of diffusion weighted imaging (DWI), making it problematic to substitute DWI in selecting individual AIS patients for reperfusion treatment.

Based on those studies, it is still remained unclear whether CTP can be an alternative choice to replace magnetic resonance perfusion (MRP) in AIS patients with extending therapeutic windows. So in this study, the investigators try to determine whether baseline CTP profiles have a comparable ability to MRP in identifying patients who have a robust clinical response after early reperfusion.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

REperfusion Therapy for Acute Ischemic STrOke Due to Large aRtEry Occlusion

NCT05311605

Stroke Vascular Occlusion Endovascular Treatment +2 more

RECRUITING

r-tPA Thrombolytic Therapy in Combination With Remote Ischemic Conditioning for Acute Ischemic Stroke Recovery

NCT02886390

Stroke, Acute

UNKNOWN NA

Perfusion Imaging Evaluation for Ischemic Stroke on 6-24 Hours Undergoing Endovascular Thrombectomy

NCT03502408

Stroke, Acute Cerebral Infarction

RECRUITING NA

Safety and Efficacy of Selective Intra-Arterial Cooling Infusion Combined With EVT in Acute Ischemic Stroke

NCT06485427

Acute Ischemic Stroke Hypothermia

RECRUITING NA

Intracranial Rescue Stenting for Acute Ischemic Stroke, Predictors of Outcomes

NCT04987710

Ischemic Stroke Thromboembolic Stroke

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a prospective, non-blind, single-center clinical trial to evaluate whether baseline computed tomography perfusion (CTP) profiles have a comparable ability to magnetic resonance perfusion (MRP) in identifying acute ischemia stroke (AIS) patients who have a robust clinical response after early reperfusion.

The study will enroll 1000 patients, and patients will be divided into 2 groups according to the imaging available situation (to see which can provide immediately): CTP scan group and MRP scan group.

Core: CT: cerebral blood flow \<30% of that in normal tissue / MR: ADC \< 600 ×D10-6 mm2 / s.

Hypoperfusion: CT / MR: time to maximum \>6.

For patients accepting CTP or MRP over 4.5 hours after stroke onset, only patients who meet imaging criteria (infarct core volume \< 70mL, perfusion lesion volume / infarct core volume \>1.2, and absolute mismatch \>10 mL) at baseline will receive recombinant tissue plasminogen activator (rt-PA) intravenous thrombolysis. CTP or MRP will be performed at 24 hours after thrombolytic therapy. Modified Rankin score (mRS) will be measured at 3 months after stroke onset.

Study Endpoints: Primary endpoint: mRS 0-2 at 3 months. Secondary endpoints: (1) symptomatic intracranial haemorrhage, (2) reperfusion, (3) recanalization, and (4) infarct growth at 24 hours.

Criteria:

Inclusion Criteria:

1. Provision of informed consent;
2. Male and female adults aged 18-80 years old;
3. For patients accepting CTP or MRP over 4.5 hours after stroke onset, imaging criteria: infarct core volume \<70mL, perfusion leison volume / infarct core volume \>1.2, and absolute mismatch \>10 mL.

Exclusion Criteria:

1. Standard contraindications to rt-PA;
2. Contraindication to imaging with contrast agents;
3. Pre-stroke mRS score of ≥2 (indicating previous disability);
4. Participation in any investigational study in the previous 30 days;
5. Any terminal illness such that patient would not be expected to survive more than one-year.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Stroke

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Computed Tomography Perfusion (CTP)

inspection mode

Intervention Type OTHER

different inspection modes：Computed Tomography Perfusion (CTP) or Magnetic Resonance Perfusion (MRP)

Magnetic Resonance Perfusion (MRP)

inspection mode

Intervention Type OTHER

different inspection modes：Computed Tomography Perfusion (CTP) or Magnetic Resonance Perfusion (MRP)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

inspection mode

different inspection modes：Computed Tomography Perfusion (CTP) or Magnetic Resonance Perfusion (MRP)

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Provision of informed consent;
2. Male and female adults aged 18-80 years old;
3. For patients accepting CTP or MRP over 4.5 hours after stroke onset, imaging criteria: infarct core volume \<70mL, perfusion leison volume / infarct core volume \>1.2, and absolute mismatch \>10 mL.

Exclusion Criteria

1. Standard contraindications to rt-PA;
2. Contraindication to imaging with contrast agents;
3. Pre-stroke mRS score of ≥2 (indicating previous disability);
4. Participation in any investigational study in the previous 30 days;
5. Any terminal illness such that patient would not be expected to survive more than one-year.

Eligible Sex

ALL

Accepts Healthy Volunteers

No